Adding Ribociclib to Letrozole Improves PFS in HR+ Advanced Breast Cancer

Share this content:
Adding ribociclib to letrozole is well tolerated, and significantly improves progression-free survival.
Adding ribociclib to letrozole is well tolerated, and significantly improves progression-free survival.

Adding ribociclib to letrozole is well tolerated, and significantly improves progression-free survival compared with letrozole alone, among postmenopausal, treatment-naive patients with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer, according to a study presented at the European Society for Medical Oncology (ESMO) 2016 Congress.1

Although endocrine therapy is frequently used as first-line therapy for advanced breast cancer, most patients eventually develop resistance and disease progression occurs. Ribociclib is a cyclin-dependent kinase 4/6 inhibitor that may help to overcome or delay resistance to endocrine therapy. Researchers evaluated the efficacy and safety of ribociclib plus letrozole as first-line therapy for patients with HR+, HER2– advanced breast cancer.

For the multicenter, double-blind, phase 3 MONALEESA-2 study (ClinicalTrials.gov Identifier: NCT01958021), investigators enrolled 668 patients who had received no prior therapy for advanced disease. Participants were randomly assigned 1:1 to receive letrozole plus ribociclib or placebo.

An interim analysis showed that median progression-free survival had not yet been reached (95% CI, 19.3-not estimable) in the ribociclib arm, versus 14.7 months (95% CI, 13.0-16.5) in the placebo arm. Patients treated with ribociclib had a 44% reduced risk of progression or death compared with those who received letrozole alone (hazard ratio, 0.556; 95% CI, 0.429-0.720; P = .00000329).

RELATED: Tamoxifen Linked With Reduced Contralateral Breast Cancer Risk

Fifty-three percent of ribociclib-treated patients achieved a response versus 37% of those in the placebo group (P = .00028). The clinical benefit rate was 80% and 72%, respectively (P = .02).

The rates of discontinuation due to adverse events were 7.5% in the ribociclib arm and 2.1% in the placebo arm, respectively.                           

Reference

  1. Hortobagyi GN, Stemmer SM, Burris HA, et al. First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC). Paper presented at: European Society for Medical Oncology (ESMO) 2016 Congress; October 7-11, 2016; Copenhagen, Denmark.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs